Harmony Biosciences Holdings, Inc. (HRMY)
NASDAQ: HRMY · Real-Time Price · USD
37.97
-0.08 (-0.21%)
At close: Aug 28, 2025, 4:00 PM
38.87
+0.90 (2.37%)
After-hours: Aug 28, 2025, 7:38 PM EDT
HRMY Employees
Harmony Biosciences Holdings had 268 employees as of December 31, 2024. The number of employees increased by 22 or 8.94% compared to the previous year.
Employees
268
Change (1Y)
22
Growth (1Y)
8.94%
Revenue / Employee
$2,882,563
Profits / Employee
$675,015
Market Cap
2.18B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 268 | 22 | 8.94% |
| Dec 31, 2023 | 246 | 46 | 23.00% |
| Dec 31, 2022 | 200 | 20 | 11.11% |
| Dec 31, 2021 | 180 | 30 | 20.00% |
| Dec 31, 2020 | 150 | 0 | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
HRMY News
- 2 days ago - Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress - Business Wire
- 7 days ago - Harmony Biosciences to Participate in 2025 Cantor Global Healthcare Conference - Business Wire
- 8 days ago - Harmony Biosciences: Reiterating Buy Ahead Of Data Catalyst For Cannabinoid Drug - Seeking Alpha
- 23 days ago - Harmony Biosciences Holdings, Inc. (HRMY) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 23 days ago - Harmony Biosciences Reports Strong Q2 2025 Financial Results and Reaffirms 2025 Revenue Guidance; On Track to Announce Fragile X Topline Data From Phase 3 Registrational Trial in Q3 2025 - Business Wire
- 5 weeks ago - Harmony Biosciences to Report Second Quarter 2025 Financial Results on August 5, 2025 - Business Wire
- 6 weeks ago - Harmony Biosciences to Participate in H.C. Wainwright "HCW@Home" Series - Business Wire
- 2 months ago - Harmony Biosciences Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 in Narcolepsy at SLEEP 2025 - Business Wire